OKY 046

Known as: OKY-046 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
BACKGROUND Because thromboxane A2 is implicated in the pathophysiology of acute lung injury, the aim of this study was to… (More)
Is this relevant?
1998
1998
The preventive effect of the serine protease inhibitor FUT-175 (nafamostat mesilate), a potent inhibitor of the complement system… (More)
Is this relevant?
1997
1997
Ciclosporin A (CsA) is a potent immunosuppressive agent which is extremely effective in controlling allograft rejection and in… (More)
Is this relevant?
1994
1994
The present study was undertaken to evaluate the effects of a selective thromboxane synthetase inhibitor (OKY-046) on urinary… (More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Renal interstitial fibrosis is a common consequence of chronic ureteral obstruction. While several cytokines may initiate… (More)
Is this relevant?
1990
1990
To determine whether the involvement of thromboxane A2 in bronchial hyperresponsiveness (BHR) is specific to asthma, we examined… (More)
Is this relevant?
1989
1989
A double-blind study was conducted at 48 neurosurgical services in Japan to investigate the usefulness of OKY-046, an imidazole… (More)
Is this relevant?
1986
1986
To determine the role of thromboxane A2 in the airway hyperresponsiveness induced by antigen challenge, we studied the effect of… (More)
Is this relevant?
1986
1986
Acute renal failure (ARF) was associated with increased urinary thromboxane (TXA2) excretion and lessened excretion of sodium… (More)
Is this relevant?
1986
1986
The effect of a selective thromboxane synthetase inhibitor, OKY-046, and a selective 5-lipoxygenase inhibitor, AA-861, on… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?